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EVIDENCE-BASED ANSWER
A
 What are the adverse eff ects 
of prolonged opioid use 
in patients with chronic pain?
 constipation, nausea, and
 dyspepsia are the most common 
long-term adverse eff ects of chronic opioid 
use (strength of recommendation [SOR]: B, 
systematic review of low-quality studies). 
Men may experience depression, fatigue, 
and sexual dysfunction (SOR: B, 2 obser-
vational studies). Prolonged use of opioids 
also may increase sensitivity to pain (SOR: 
C, review of case reports and case series). 
(Th is review does not address drug seeking 
or drug escalating.)
Patients on long-term methadone are 
at risk for cardiac arrhythmias caused by 
prolonged QT intervals and torsades de 
pointes (SOR: C, case reports). 
Patients taking buprenorphine for 
opioid dependence may experience acute 
hepatitis (SOR: C, 1 case report). 
Evidence summary 
Chronic pain is usually defi ned as pain per-
sisting longer than 3 months. Evidence of the 
effi  cacy of opioids for noncancer pain has led 
to increased opioid prescribing over the past 
20 years and with it, growing concern about 
adverse eff ects from long-term use.1
Nausea, constipation, dyspepsia 
lead side-effects parade
A Cochrane systematic review of 26 studies 
(25 observational studies and 1 randomized 
controlled trial [RCT]) of adults who had 
taken opioids for noncancer pain for at least 
6 months assessed the adverse eff ects of 
long-term opioid therapy.2 Although the 
authors couldn’t quantify the incidence of 
adverse eff ects because of inconsistent re-
porting and defi nition of eff ects, they stated 
that the most common complications were 
nausea, constipation, and dyspepsia. Th e re-
view found that 22.9% of patients (95% con-
fi dence interval [CI], 15.3-32.8) discontinued 
oral opioids because of adverse eff ects.
A cross-sectional observational study 
evaluated self-reported adverse eff ects in 
889 patients who received opioid therapy for 
noncancer pain lasting at least 3 months.3 
Forty percent of patients reported constipa-
tion and 18% sexual dysfunction. Patients 
taking opioids daily experienced more con-
stipation than patients taking the drugs in-
termittently (39% vs 24%; number needed to 
harm [NNH]=7; P<.05).
Sexual dysfunction, fatigue, 
depression aren’t far behind
A case-control study of 20 male cancer sur-
vivors with neuropathic pain who took 
200 mg of morphine-equivalent daily for a 
year found that 90% of patients in the opi-
oid group experienced hypogonadism with 
symptoms of sexual dysfunction, fatigue, and 
depression, compared with 40% of the 20 
controls (NNH=2; 95% CI, 1-5).4
A case-controlled observational study of 
54 men with noncancer pain who took opi-
oids for 1 year found that 39 of 45 men who 
had normal erectile function before opioid 
therapy reported severe erectile dysfunction 
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while taking the drugs.5 Levels of testoster-
one and estradiol were signifi cantly lower 
(P<.0001) in the men taking opioids than the 
27 opioid-free controls.
Potentially fatal arrhythmias 
are a risk for some patients
From 1969 to 2002, 59 cases of QT prolonga-
tion or torsades de pointes in methadone us-
ers, 5 (8.5%) of them fatal, were reported to 
the US Food and Drug Administration’s Med-
watch Database.6 Th e mean daily methadone 
dose was 410 mg (median dose 345 mg, range 
29-1680 mg). Length of therapy was not re-
ported. In 44 (75%) of reported cases, patients 
had other known risks for QT prolongation 
or torsades de pointes, including female sex, 
interacting medications, potassium or mag-
nesium abnormalities, and structural heart 
disease. 
Buprenorphine may cause 
acute hepatitis
No apparent long-term hepatic adverse eff ects 
are associated with chronic opioid use. Howev-
er, a 2004 case series described acute cytolytic 
hepatitis in 7 patients taking buprenorphine, 
all with hepatitis C and a history of intravenous 
drug abuse.7 Acute symptoms resolved quickly 
in all cases, and only 3 patients required a re-
duction in buprenorphine dosage.
Prolonged use may increase
sensitivity to pain
Case reports and case series have found that 
prolonged use of opioids causes increased 
sensitivity to pain in some patients, which is 
diffi  cult to diff erentiate from opioid tolerance.8
Recommendations 
Th e American Pain Society (APS) recom-
mends anticipating, identifying, and treating 
opioid-related adverse eff ects such as consti-
pation or nausea.1 APS advises against using 
opioid antagonists to prevent or treat bowel 
dysfunction, and encourages older patients 
or patients with an increased risk of devel-
oping constipation to start a bowel regimen. 
Patients with complaints suggesting hypo-
gonadism should be tested for hormonal 
defi ciencies. 
Th e Center for Substance Abuse and 
Treatment recommends obtaining a cardiac 
history and an electrocardiogram (EKG) on 
all patients before starting methadone and 
repeating the EKG at 30 days and annually 
thereafter to evaluate for QT prolongation.9
Prescribers should also warn patients of the 
risk of methadone-induced arrhythmias and 
be aware of interacting medications that pro-
long the QT interval or reduce methadone 
elimination.                JFP
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